| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-03-23 |
| タイトル |
|
|
タイトル |
The role of nitric oxide in inflammation, tumor microenvironment, and cancer therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Cancer |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Inflammation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Nitric oxide |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Peroxynitrite |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Reactive nitrogen species |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Tumor microenvironment |
| キーワード |
|
|
言語 |
en |
|
キーワード |
iNOS |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Nair, Akhil
マドゥエスタ, ハリーシャクマール
WEKO
7810
| en |
Madhyastha, Harishkumar
University of Miyazaki
|
| ja |
マドゥエスタ, ハリーシャクマール
宮崎大学
|
| ja-Kana |
マドゥエスタ, ハリーシャクマール
|
Search repository
Revanasiddappa, B C
Pai, Vasudev
Kumar, Dileep
Neenu, M K
Prabhu, Pavithra Pradeep
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Nitric oxide (NO) is a widespread signaling molecule which has far-reaching effects in cellular physiology and pathophysiology, especially in cancer biology. Its actions are concentration-dependent where low concentrations facilitate tumor development and high concentrations cause cytotoxicity. NO alters several cancer hallmarks, affecting the initiation, progression, immune evasion, and therapeutic responses of tumors via cGMP-dependent and -independent pathways. Various cell types in the tumor microenvironment (TME) produce NO in a concentration gradient creating a strong concentration gradient that forms the immune landscape. NO mediates immunosuppression through the regulation of tumor-associated macrophage, myeloid-derived suppressor cell, T cells, and natural killer cells. It also controls angiogenesis and normalization of the vasculature via the VEGF-NO axis. Moreover, NO effects epithelial-mesenchymal transition and metastasis concentration-dependently. Notably, NO exists in a complex interaction with gasotransmitters, and it interacts with hydrogen sulfide and carbon monoxide in crosstalk to control cancer biology. Therapeutic interventions that focus on NO e.g., NO donors, iNOS-inhibitors and nanodelivery systems have been promising in preclinical practice. Nevertheless, clinical translation is complicated by the fact that the concentrations of intratumoral NO have to be tightly controlled, safety issues exist, and there are not many biomarkers of patient stratification. Integration of NO-based therapies with immunotherapy and precision medicine approaches holds promise for enhancing treatment outcomes. Continued research spanning chemical, biological, and clinical domains is crucial for unlocking the full therapeutic potential of NO in cancer. |
|
言語 |
en |
| 書誌情報 |
en : Nitric oxide : biology and chemistry
巻 162,
p. 25-34,
発行日 2026-06
|
| 出版者 |
|
|
出版者 |
Elsevier BV |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
10898611 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.niox.2026.02.005 |
| 権利 |
|
|
権利情報 |
© 2026 The Authors. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (1.9 MB)
.png)
